BBlogFlow

Large cognitive health study links speech patterns with brain aging - The Brighter Side of News

·Oct 3, 2026
Source: The Brighter Side of News
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

A study of 2,928 Spanish-speaking adults linked older-appearing speech profiles with several measures of brain and biological aging. Larger speech-age gaps were associated with poorer cognition, dementia diagnoses and greater social adversity, although patterns varied across groups. The research does not establish whether speech recordings can predict future dementia or track an individual’s aging rate over time. The pace, pitch and word choices of everyday speech may carry clues about aging that extend beyond a person’s voice. A large Latin American study found that older-appearing speech profiles were associated with brain aging, memory difficulties and molecular markers of biological aging. The findings, published in Science Advances, come from 2,928 Spanish-speaking participants across Argentina, Chile, Colombia, Mexico and Peru. The research involved the Multi-Partner Consortium to Expand Dementia Research in Latin America, known as ReDLat. Senior author Agustin Ibanez is a professor at Trinity College Dublin’s Global Brain Health Institute and School of Medicine.

This article is an excerpt. To read the full content, visit the original source. The Brighter Side of News

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.

Oncodaily·